Fintel reports that on October 2, 2023, Cantor Fitzgerald reiterated coverage of Lilly (NYSE:LLY) with a Overweight recommendation.
Analyst Price Forecast Suggests 3.59% Upside
As of August 31, 2023, the average one-year price target for Lilly is 557.61. The forecasts range from a low of 303.00 to a high of $664.65. The average price target represents an increase of 3.59% from its latest reported closing price of 538.28.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Lilly is 30,424MM, an increase of 3.08%. The projected annual non-GAAP EPS is 9.24.
What is the Fund Sentiment?
There are 4260 funds or institutions reporting positions in Lilly. This is an increase of 160 owner(s) or 3.90% in the last quarter. Average portfolio weight of all funds dedicated to LLY is 0.96%, an increase of 18.54%. Total shares owned by institutions decreased in the last three months by 6.01% to 867,614K shares. 
The put/call ratio of LLY is 0.89, indicating a bullish outlook.
What are Other Shareholders Doing?
Lilly Endowment holds 101,029K shares representing 11.23% ownership of the company. In it's prior filing, the firm reported owning 102,544K shares, representing a decrease of 1.50%.
Pnc Financial Services Group holds 51,870K shares representing 5.77% ownership of the company. In it's prior filing, the firm reported owning 51,922K shares, representing a decrease of 0.10%. The firm increased its portfolio allocation in LLY by 549.86% over the last quarter.
Capital World Investors holds 26,868K shares representing 2.99% ownership of the company. In it's prior filing, the firm reported owning 27,589K shares, representing a decrease of 2.68%. The firm increased its portfolio allocation in LLY by 23.75% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 26,649K shares representing 2.96% ownership of the company. In it's prior filing, the firm reported owning 26,476K shares, representing an increase of 0.65%. The firm increased its portfolio allocation in LLY by 26.82% over the last quarter.
Price T Rowe Associates holds 24,161K shares representing 2.69% ownership of the company. In it's prior filing, the firm reported owning 22,723K shares, representing an increase of 5.95%. The firm increased its portfolio allocation in LLY by 204.94% over the last quarter.
Lilly Background Information
(This description is provided by the company.)
Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. It was founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today it remains true to that mission in all its work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
